• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Eli Lilly

Eli Lilly

Eli Lilly and Co LLY 2 Star

Last Price$70.39Day Change (%)0.33%
Open Price$70.29Day Change ($)0.23
Day Range70.26–70.9952-Week Range50.51–75.10

As of Fri 12/26/2014 05:03 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan

    Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabledâ„¢ Melphalan

  2. FDA Approves Eli Lilly's Cyramza for Lung Cancer

    FDA Approves Eli Lilly's Cyramza for Lung Cancer

  3. UPDATE: S&P 500 rattles cage on uncharted -2-

    UPDATE: S&P 500 rattles cage on uncharted -2-

  4. S&P 500 rattles cage on uncharted territory -2-

    S&P 500 rattles cage on uncharted territory -2-

  5. Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology

    Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology

  6. Lilly Sets Dates and Conference Calls for 2015 Financial Guidance and Fourth-Quarter 2014 Financial Results

    Lilly Sets Dates and Conference Calls for 2015 Financial Guidance and Fourth-Quarter 2014 Financial Results

  7. Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers

    Our Ultimate Stock-Pickers Index continues to beat the market even as relatively few of our top managers are outperforming the S&P 500.

  8. Research and Markets: Diabetic Neuropathic Pain - Pipeline Review, H2 2014

    Research and Markets: Diabetic Neuropathic Pain - Pipeline Review, H2 2014

  9. Research and Markets: Mild Cognitive Impairment - Pipeline Review, H1 2014

    Research and Markets: Mild Cognitive Impairment - Pipeline Review, H1 2014

  10. Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

    Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.